{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-007771","form_type":"8-K","ticker":null,"cik":"0001178711","company_name":"Paratek Pharmaceuticals, Inc.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.064695+00:00","generated_at":"2026-06-18T02:52:28.995671+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Paratek amends bylaws to comply with SEC universal proxy rules and DGCL updates","bullets":["Board approved Amended and Restated Bylaws effective March 9, 2023.","Bylaws update procedural requirements for stockholder director nominations under SEC universal proxy rules.","Removes requirement to produce a stockholder list at meetings; adds Rule 14a-19 compliance mandate.","Prohibits additional or substitute nominations after the deadline and requires stockholder appearance at meetings.","Reserves white proxy cards for company use; other solicitors must use a different color."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-007771","json":"https://secwatch.observer/filing/0001628280-23-007771.json","markdown":"https://secwatch.observer/filing/0001628280-23-007771.md","text":"https://secwatch.observer/filing/0001628280-23-007771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178711/000162828023007771/0001628280-23-007771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178711/000162828023007771/prtk-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T02:52:28.995671+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1801ca63a0bfa2cba6ac7c93683d648fc784709b","claim":"Paratek Pharmaceuticals, Inc.: Amended and restated bylaws to update procedural requirements for director nominations and other administrative changes, effective March 9, 2023 (effective 2023-03-09).","evidence_excerpt":"On March 9, 2023 the Board of Directors (the “Board”) of Paratek Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”), effective as of such date.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178711/000162828023007771/0001628280-23-007771-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-09"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}